In this case report, we describe the treatment of a young patient with end-stage AIDS, disseminated kaposi sarcoma and COVID-19 infection with molnupravir. With a positive SARS-CoV-2 test, a woman who had never received antiretroviral therapy was admitted to our hospital. On physical examination, multiple small purple maculopapular lesions were present on the body. In the laboratory findings HIV RNA was 255.000 copies, CD4:7 u/L. Tenofovir+ emtricitabine/dolutegravir was started for HIV treatment. Skin biopsy was found to be compatible with Kaposi's sarcoma. The patient's swab every other day was examined for COVID-PCR and remained positive for 63 days. Due to the necessity of oncological treatment, antiviral molnupiravir 2*800 mg treatment was started for 5 days. COVID-PCR performed 4 days after molnupravir treatment and it was negative. We think that early initiation of antiviral treatment is important for PCR negativity and early access to oncological treatment especially in end-stage COVID-positive AIDS cases.